CN118027039A - 一种取代的哌嗪衍生物的晶体及其制备方法 - Google Patents

一种取代的哌嗪衍生物的晶体及其制备方法 Download PDF

Info

Publication number
CN118027039A
CN118027039A CN202311526331.4A CN202311526331A CN118027039A CN 118027039 A CN118027039 A CN 118027039A CN 202311526331 A CN202311526331 A CN 202311526331A CN 118027039 A CN118027039 A CN 118027039A
Authority
CN
China
Prior art keywords
crystal
powder diffraction
ray powder
crystal form
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311526331.4A
Other languages
English (en)
Chinese (zh)
Inventor
刘兆军
楚洪柱
朱钰沁
曹鑫
魏用刚
孙毅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kangbaida Sichuan Biopharmaceutical Technology Co ltd
Original Assignee
Chengdu Baiyu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Baiyu Pharmaceutical Co Ltd filed Critical Chengdu Baiyu Pharmaceutical Co Ltd
Publication of CN118027039A publication Critical patent/CN118027039A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN202311526331.4A 2022-11-14 2023-11-14 一种取代的哌嗪衍生物的晶体及其制备方法 Pending CN118027039A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022114177213 2022-11-14
CN202211417721 2022-11-14

Publications (1)

Publication Number Publication Date
CN118027039A true CN118027039A (zh) 2024-05-14

Family

ID=90997576

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202311526331.4A Pending CN118027039A (zh) 2022-11-14 2023-11-14 一种取代的哌嗪衍生物的晶体及其制备方法

Country Status (9)

Country Link
US (1) US20250270223A1 (https=)
EP (1) EP4620958A1 (https=)
JP (1) JP2025536416A (https=)
KR (1) KR20250086779A (https=)
CN (1) CN118027039A (https=)
AU (1) AU2023381502A1 (https=)
MX (1) MX2025005591A (https=)
TW (1) TWI879228B (https=)
WO (1) WO2024104354A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025036478A1 (zh) * 2023-08-17 2025-02-20 康百达（四川）生物医药科技有限公司 一种哌嗪衍生物的药物制剂、其制备方法及其用途
WO2025209574A1 (zh) * 2024-04-03 2025-10-09 康百达（四川）生物医药科技有限公司 用于预防或治疗肿瘤的parp7抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3788040T3 (fi) * 2018-04-30 2023-06-13 Ribon Therapeutics Inc Pyridatsinoneja parp7-inhibiittoreina
WO2020223229A1 (en) * 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
CN112745312B (zh) * 2019-10-30 2022-08-30 沈阳中化农药化工研发有限公司 哒嗪酮异恶唑甲醚类化合物及其应用
US20240190844A1 (en) * 2019-10-30 2024-06-13 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
CN116157396B (zh) * 2020-11-27 2025-07-18 康百达（四川）生物医药科技有限公司 哒嗪酮衍生物及其在医药上的应用
WO2022156708A1 (en) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor
KR20240012534A (ko) * 2021-05-21 2024-01-29 청두 바이위 파머수티컬 씨오., 엘티디 피페라진 유도체 및 이의 의학적 용도

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025036478A1 (zh) * 2023-08-17 2025-02-20 康百达（四川）生物医药科技有限公司 一种哌嗪衍生物的药物制剂、其制备方法及其用途
WO2025209574A1 (zh) * 2024-04-03 2025-10-09 康百达（四川）生物医药科技有限公司 用于预防或治疗肿瘤的parp7抑制剂

Also Published As

Publication number Publication date
TW202426452A (zh) 2024-07-01
WO2024104354A1 (zh) 2024-05-23
MX2025005591A (es) 2025-06-02
TWI879228B (zh) 2025-04-01
AU2023381502A1 (en) 2025-05-15
EP4620958A1 (en) 2025-09-24
US20250270223A1 (en) 2025-08-28
JP2025536416A (ja) 2025-11-05
KR20250086779A (ko) 2025-06-13

Similar Documents

Publication Publication Date Title
CN113544128A (zh) Kras-g12c抑制剂
WO2023116895A1 (zh) Kras抑制剂的多晶型物及其制备方法和用途
US20250270223A1 (en) Crystal of substituted piperazine derivative and preparation method therefor
JP2019521980A (ja) Ｊａｋ阻害剤としてのピロロピリミジン化合物の結晶
CN114929701B (zh) 一种pde3/pde4双重抑制剂的结晶及其应用
CN112110938B (zh) 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
CN112142745A (zh) 一种酪蛋白激酶1ε抑制剂、药物组合物及其应用
CN111777595A (zh) 一种环己烷甲酰胺类化合物的新晶型及其制备方法
US20230002393A1 (en) Cdk kinase inhibitor
JP2023535361A (ja) ピリミジン系化合物の塩、結晶形およびその調製方法
CN118632843A (zh) 一种吡啶类衍生物及其用途
US20210261546A1 (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
CN113880804A (zh) 新型苯并咪唑化合物
CN116239603A (zh) 一种2-氨基嘧啶杂环类化合物及其应用
CN107056771A (zh) Bromodomain蛋白二价抑制剂及其制备方法和应用
WO2024235289A1 (zh) 用于egfr蛋白降解的化合物及其用途
EP3941472B1 (en) Crystalline and amorphous forms of-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2 <ns1:i>h</ns1:i>?-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
HK40104801A (zh) 一种取代的哌嗪衍生物的晶体及其制备方法
CN108299419B (zh) 一种新型egfr激酶抑制剂的几种新晶型及其制备方法
KR20220143666A (ko) 다환 역형성 림프종 키나아제 억제제의 결정형
TWI919884B (zh) 一種嘧啶并氮雜環類化合物的晶型及其製備方法及應用
WO2022099442A1 (zh) 5-氟-1-(4-氟-3-(4-(嘧啶-2-基)哌嗪-1-羰基)苄基)喹唑啉-2,4(1h,3h)-二酮的结晶形式及其制备
CA3104365C (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
WO2025223554A1 (zh) 一种嘧啶并氮杂环类化合物的晶型及其制备方法及应用
WO2026021534A1 (zh) 一种嘧啶类衍生物的固体形式及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40104801

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20240902

Address after: No. 433, Anxian Road, Section 3, Qiqi Avenue, Wenjiang District, Chengdu, Sichuan 610000

Applicant after: Kangbaida (Sichuan) Biopharmaceutical Technology Co.,Ltd.

Country or region after: China

Address before: 611130 b7-10 / F, Tianfu Life Science Park, 88 Keyuan South Road, high tech Zone, Chengdu, Sichuan

Applicant before: CHENGDU BAIYU PHARMACEUTICAL Co.,Ltd.

Country or region before: China

TA01 Transfer of patent application right